Torpex gets FDA nod; ranks as first MDI

Boehringer Ingelheim Vetmedica Inc. recently launched Torpex aerosolalbuterol sulfate, a dose inhaler approved for use in horses suffering fromreversible airway obstruction. Torpex is labeled for the immediate reliefof bronchospasms and bronchoconstriction associated with reversible airwayobstruction in horses. The hand-held metered dose inhaler (MDI) also hasa patented anatomically correct bulb for the left nostril of the horse.Dr. Robert M. Stenbom, equine technical manager for Boehringer Ingelheim,says that the unique design provides an excellent delivery mechanism ofthe product to the lungs. The device was created jointly by 3M and Boehringer.Stenbom adds, "Each actuation of the MDI device delivers 120 microgramsof aerosol albuterol sulfate to the horse's airway. One dose is three actuations(puffs) for a total delivery of 360 micrograms of Torpex. Dr. Jane Smith,Boehringer's equine segment manager, adds, "Torpex is the first andonly FDA-approved MDI, approved for the immediate relief of bronchospasmand bronchoconstriction associated with reversible airway obstruction inhorses. Long-term clinical and field studies demonstrate that when the productis used according to directions, it provides fast-acting, short-term bronchodilationin horses," she adds. Key components of the metered dose inhaler include:o A disposable inhaler with a cleanable bulb. o Drug incorporated in anozone-friendly propellant. o There are 200-plus actuations in every device.o Onset of action in five to 10 minutes. o Duration of action, one to sevenhours.

For fastest response call (800) 325-9167 .